Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine

Abstract We evaluated the immunologic response to a novel vaccine regimen that included 2 doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent booster vaccine. A durable neutralizing antibody response to Omicron BA.4/BA.5 and BA.1 variants was observed at month...

Full description

Saved in:
Bibliographic Details
Published inOpen forum infectious diseases Vol. 11; no. 2; p. ofad673
Main Authors Babu, Tara M, Shen, Xiaoying, McClelland, R Scott, Wang, Zijun, Selke, Stacy, Wilkens, Chloe, Hauge, Kirsten A, McClurkan, Christopher L, Goecker, Erin, Laing, Kerry J, Koelle, David M, Greninger, Alexander L, Nussenzweig, Michel C, Montefiori, David C, Corey, Lawrence, Wald, Anna
Format Journal Article
LanguageEnglish
Published US Oxford University Press 01.02.2024
Subjects
B cells
Coronaviruses
Health aspects
Pharmaceutical industry
RNA
Severe acute respiratory syndrome
Vaccines
Vaccines and Immunization
United States
SARS-CoV-2
vaccine
antibody
virus
Online AccessGet full text

Cover

More Information
Summary:Abstract We evaluated the immunologic response to a novel vaccine regimen that included 2 doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent booster vaccine. A durable neutralizing antibody response to Omicron BA.4/BA.5 and BA.1 variants was observed at month 6 after the booster, while immune escape was noted for the XBB.1.5 variant.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Presented in part: ID Week, Washington, DC, October 2022; Annual Meeting of the Infectious Diseases Clinical Research Consortium, Washington, DC, April 24, 2023.
Potential conflicts of interest . Z. W. was supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health (NIH) Clinical and Translational Science Award program (grant UL1 TR001866). D. M. K. discloses support from the National Institute of Allergy and Infectious Diseases (contract 75N93019C00063) and the NIH (grant AI163999). A. L. G. reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen, and Hologic and research support from Gilead, outside the described work. M. C. N. is on the scientific advisory board of Frontier Bio, Aerium Therapeutics, Walking Fish, and Apriori Bio and is a Howard Hughes Medical Institute investigator. The Rockefeller University licensed anti–human immunodeficiency virus antibodies cloned in M. C. N.’s laboratory to Gilead. D. C. M. receives funding from NIH and Moderna for laboratory studies of coronavirus disease 2019 vaccine antibody responses. All other authors report no potential conflicts.
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofad673